Filing Details
- Accession Number:
- 0001209191-14-075578
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-15 21:49:45
- Reporting Period:
- 2014-12-11
- Filing Date:
- 2014-12-15
- Accepted Time:
- 2014-12-15 21:49:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Biosciences Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1234386 | Ii O Edward Lanphier | C/O Sangamo Biosciences Inc., Point Richmond Tech Cntr, 501 Canal Blvd Richmond CA 94804 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-12-11 | 125,000 | $0.00 | 420,000 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2014-12-15 | 96,533 | $14.74 | 323,467 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2014-12-15 | 25,000 | $4.11 | 348,467 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-12-15 | 9,000 | $16.47 | 339,467 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-12-15 | 16,000 | $14.79 | 323,467 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Acquisiton | 2014-12-11 | 250,000 | $0.00 | 250,000 | $14.07 |
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2014-12-15 | 25,000 | $0.00 | 25,000 | $4.11 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 250,000 | 2024-12-10 | No | 4 | A | Direct | |
| 0 | 2015-12-11 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,516,054 | Indirect | By Trust |
Footnotes
- Shares subject to restricted stock units ("RSUs"), which will vest in a series of three successive equal annual installments upon the Reporting Person's completion of each year of service over the three year period from the grant date.
- Includes 60,000 and 50,000 shares subject to RSUs granted on December 6, 2012 and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
- Represents shares withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting and issuance of RSUs.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.56, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2014.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.73 to $15.01, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- These shares are held in the Edward O. Lanphier II and Cameron M. Lanphier Trust U/T/A August 30, 2002, Edward O. Lanphier II and Cameron M. Lanphier, Trustees.
- The stock option vests and becomes exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured form the grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.
- All shares underlying these options are vested and exercisable immediately and such option will expire on December 11, 2015.
Billionaire Hedge Funds
